Early liquid biopsy in advanced non-small cell lung cancer: insights from the LIBELULE trial

Key Points

• Advanced non-small cell lung cancer patients showed promising results from liquid biopsy.
• The LIBELULE trial identified critical biomarkers through circulating tumor DNA analysis.
• Evaluation utilized an observational analysis across various healthcare settings to assess liquid biopsy efficacy.
• These findings may enable earlier diagnosis and improve treatment outcomes for lung cancer patients.